scholarly journals Efficacy of Imiquimod Cream, 5%, for Lentigo Maligna After Complete Excision

2011 ◽  
Vol 147 (10) ◽  
pp. 1191 ◽  
Author(s):  
Lena Ly
Keyword(s):  
Lentigo Maligna ◽  
Imiquimod Cream ◽  
Complete Excision

A practical guide on the use of imiquimod cream to treat lentigo maligna

2021 ◽  
Author(s):  
Pascale Guitera ◽  
Andreanne Waddell ◽  
Elizabeth Paton ◽  
Gerald B Fogarty ◽  
Angela Hong ◽  
...  
Keyword(s):  
Lentigo Maligna ◽  
Imiquimod Cream ◽  
Practical Guide

Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study

2016 ◽  
Vol 74 (1) ◽  
pp. 81-87.e1 ◽  
Author(s):  
Mirja Gautschi ◽  
Patrick A. Oberholzer ◽  
Marc Baumgartner ◽  
Karolina Gadaldi ◽  
Nikhil Yawalkar ◽  
...  
Keyword(s):  
Prognostic Markers ◽  
Lentigo Maligna ◽  
Imiquimod Cream ◽  
Follow Up Study ◽  
Long Term Follow Up

scholarly journals Comparing preoperative mapping with reflectance confocal microscopy to surgical markings in lentigo maligna excision of the face: a pilot study

2020 ◽  
Vol 3 (2) ◽  
Author(s):  
Lipi Shukla ◽  
Louise Photiou ◽  
Alan Pham ◽  
Catriona McLean ◽  
Raquel Ruiz ◽  
...  
Keyword(s):  
Pilot Study ◽  
Confocal Microscopy ◽  
Surgical Margin ◽  
Surgical Excision ◽  
Reflectance Confocal Microscopy ◽  
Histopathological Analysis ◽  
Lentigo Maligna ◽  
Complete Excision ◽  
Preoperative Mapping

Background: Lentigo maligna (LM) characteristically has an ill-defined margin and may require multiple excisions to achieve complete excision with 5mm margins. In vivo reflectance confocal microscopy (RCM) is a non-invasive tool recognised as useful in the management of LM. The authors aimed to determine whether the use of RCM prior to surgical excision reliably increased the rate of complete excision when compared with standard surgical excision. Methods: This prospective pilot study included patients with biopsy-proven LM of head and neck region who sought consultation for surgical management from May 2017 to May 2019 at the Victorian Melanoma Service, Melbourne. Patients were randomised to two groups based on the availability of RCM — Group 1, RCM-guided surgical excision, and Group 2, standard surgical excision. Outcomes were measured based on clinical markings and histopathological margins achieved and reported as RCM or surgical margin excess or deficit. Ethics approval for the study was obtained from the Research Governance Unit of The Alfred Hospital, Melbourne. Results: Results demonstrated that RCM marking of lesion margins was in excess in 69 percent of cases, in deficit in 22 per cent and accurate in nine per cent after histopathological analysis of the specimens. In comparison, lesions that were surgically marked were removed with margins in excess in 43 per cent of cases, in deficit in 11 per cent and accurate in 46 per cent. Conclusion: This pilot study demonstrates that RCM did not increase the accuracy of LM surgical excision in comparison with standard surgically marked excisions.

A pilot study of treatment of lentigo maligna with 5% imiquimod cream

2004 ◽  
Vol 151 (2) ◽  
pp. 485-488 ◽  
Author(s):  
C.J. Fleming ◽  
A.M. Bryden ◽  
A. Evans ◽  
R.S. Dawe ◽  
S.H. Ibbotson
Keyword(s):  
Pilot Study ◽  
Lentigo Maligna ◽  
Imiquimod Cream

Histologic Resolution of Melanoma In Situ (Lentigo Maligna) With 5% Imiquimod Cream

2003 ◽  
Vol 139 (7) ◽  
Author(s):  
M. Shane Chapman ◽  
Steven K. Spencer ◽  
Jeoffry B. Brennick
Keyword(s):  
Lentigo Maligna ◽  
Imiquimod Cream ◽  
Melanoma In Situ

Topical 5% Imiquimod in the Treatment of Lentigo Maligna

2012 ◽  
Vol 16 (4) ◽  
pp. 245-249 ◽  
Author(s):  
Jessica G. Wong ◽  
Jack W.P. Toole ◽  
Alain A. Demers ◽  
Grace Musto ◽  
Marni C. Wiseman
Keyword(s):  
Effective Treatment ◽  
Tumor Size ◽  
Treatment Duration ◽  
Standard Treatment ◽  
Surgical Excision ◽  
Off Label Use ◽  
Lentigo Maligna ◽  
Imiquimod Cream ◽  
Off Label ◽  
The Mean

Background: Standard treatment for lentigo maligna (LM) is surgical excision with 5 to 10 mm margins. This can be cosmetically disfiguring. Imiquimod locally induces Toll-like receptors to release cytokines that destroy neoplastic melanocytes. Objective: The off-label use of topical 5% imiquimod cream may provide an alternative to surgery. This study reviews the use of imiquimod to treat LM. Methods: A 5-year retrospective and prospective chart analysis was conducted. Pretreatment biopsies confirmed the diagnosis. Treatment was individualized for each patient. Posttreatment biopsies and dermoscopy determined clearance of LM. Results: Twenty-seven patients were reviewed. There were 20 responders (74.1%) and 7 failures. The mean tumor size (area of an ellipse) was 6.69 cm2, and the mean treatment duration was 17.68 weeks. Neither the size of the tumor ( p = .86) nor treatment duration ( p = .18) was related to resolution of the lesion. Conclusion: Imiquimod is an effective treatment for LM that provides patients with a cosmetically favorable outcome when standard surgery is not an option.

Sign in / Sign up

Export Citation Format

Share Document